
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Clobetasol Propionate Foam.
Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Olux Foam, 0.05%, of Mylan Pharmaceuticals Inc. Clobetasol Propionate Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and older. Clobetasol Propionate Foam, 0.05% has an estimated market size of US$10 million for twelve months ending Dec 2021 according to IQVIA.Alembic has received a cumulative total of 165 ANDA approvals (141 final approvals and 24 tentative approvals) from USFDA.Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907.

Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.Information about Alembic can be found at https://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573).
Related
More Stories
Alembic reports 11% growth in revenue for Q4 FY22 from INR 1280 Cr. in FY21 to INR 1416 Cr.
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st March 2022. Financial HighlightsIndia Branded Business up...
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.Alembic Pharmaceuticals Limited (Alembic) today announced that...
Black Fungus: 11 Pharma Companies To Produce Amphotericin-B Dru
India's drug regulator has authorized five new companies to manufacture the life-saving injection used to treat Mucormycosis in an attempt...
Alembic Pharmaceuticals recieves USFDA approval for bipolar depression.
Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to...
Alembic announces upto 50 lakhs of financial aide for deceased Employees due to Covid 19
Alembic Pharmaceuticals Ltd has announced Financial Aid of between 15 lakhs to 50 lakhs to their deceased employees, which is over...
Jubilant Pharma wins over Bracco’s Legal appeals in the United States Court of Appeals
Jubilant Pharma Limited ("Jubilant"), a subsidiary of Jubilant Pharmova Limited, announced that it has received a favorable and unanimous judgment...
Average Rating